Summary: Investigators demonstrated that an experimental compound called BA-101 can successfully strip away glioblastoma’s defensive armor. By selectively blocking an enzyme that fuels the tumor’s survival, BA-101 forces drug-resistant cancer cells to become highly vulnerable to temozolomide once again, significantly slowing tumor growth and driving targeted cancer cell death in animal models.
Key Facts
- Targeting Nitrosative Stress: Drug-resistant glioblastoma tumors rely heavily on a biological process called nitrosative stress. By churning out excessive amounts of nitric oxide molecules, the tumor builds a protective chemical shield that helps it multiply, invade healthy tissue, and ignore chemotherapy.
- The nNOS Blockade Mechanism: BA-101 works as a highly selective inhibitor of neuronal nitric oxide synthase (nNOS), the specific enzyme responsible for generating that runaway nitric oxide shield.
- Dismantling Aggressive Malignancy: In laboratory trials, exposing resistant brain cancer cells to BA-101 single-handedly slowed cell growth, paralyzed their ability to migrate into healthy brain regions, lowered stress markers, and triggered apoptosis (programmed cell death).
- The Synergy Breakthrough: Most importantly, combining BA-101 with the standard drug temozolomide yielded a massive anti-cancer punch that was vastly more effective than either drug could manage on its own.
- In Vivo Success: When tested in preclinical mouse models bearing aggressive glioblastoma tumors, the dual BA-101 and temozolomide cocktail dramatically shrunk tumor mass and restricted growth compared to standalone chemo treatments.
- A New Class of Combination Therapies: Professor Haitham Amal notes that rather than trying to completely replace existing chemotherapies, this strategy introduces a new class of helper compounds built to systematically break down the exact survival tricks that tumors use to evade medicine.
Source: Hebrew University of Jerusalem
Researchers led by Postdoctoral Fellow Dr. Mallikar Nimgampalle of the Hebrew University of Jerusalem and Prof. Haitham Amal of the Hebrew University of Jerusalem and Harvard Medical School have identified a promising new approach to one of the greatest challenges in treating glioblastoma, the most aggressive and lethal form of brain cancer: resistance to chemotherapy.
Their study, published in Cancer Medicine, shows that an experimental compound, BA-101, can make drug-resistant glioblastoma cells vulnerable once again to the standard chemotherapy drug temozolomide (TMZ), significantly slowing tumor growth in preclinical models.
Glioblastoma is notoriously difficult to treat. Although surgery, radiation, and temozolomide are the current standard of care, many tumors either fail to respond or quickly develop resistance, leaving patients with few effective treatment options.
In the new study, the researchers targeted a biological process known as nitrosative stress—an imbalance caused by excessive production of nitric oxide molecules that helps tumors survive, spread, and evade treatment. They found that blocking this pathway with BA-101, a selective inhibitor of neuronal nitric oxide synthase (nNOS), substantially reduced the aggressive behavior of drug-resistant glioblastoma cells.
The treatment slowed cancer cell growth, reduced their ability to invade surrounding tissue and migrate, lowered markers of nitrosative stress, and triggered cancer cell death. Most importantly, combining BA-101 with temozolomide produced a stronger anti-cancer effect than either treatment alone, including significantly reducing tumor growth in mice.
“Temozolomide resistance remains one of the biggest obstacles in treating glioblastoma,” said Prof. Haitham Amal of the Institute for Drug Research at the Hebrew University of Jerusalem and Boston Children’s Hospital, Harvard Medical School, who led the study.
“Our findings suggest that targeting nitrosative stress can restore the tumor’s sensitivity to treatment. While additional studies are needed before this approach can reach patients, these results open an exciting new direction for developing more effective therapies against one of the deadliest cancers.”
The researchers believe the findings could pave the way for a new class of combination therapies aimed at overcoming treatment resistance rather than simply replacing existing drugs. Because BA-101 targets a mechanism that helps cancer cells survive chemotherapy, it may enhance the effectiveness of current treatments while potentially delaying the development of resistance.
The study was led by Prof. Haitham Amal, with first author Dr. Mallikarjuna Nimgampalle and co-authors Shashank Kumar Ojha, Maryam Kartawy, and Michelle Feivelson, all from the Institute for Drug Research at the Hebrew University of Jerusalem.
The researchers emphasize that BA-101 remains an experimental compound and that further preclinical studies and clinical trials will be necessary before it can be evaluated as a treatment for patients.
BA-101, the experimental neuronal nitric oxide synthase (nNOS) inhibitor used in this study, has been exclusively licensed from Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, by NeuroNOS, a biotechnology company co-founded by Prof. Haitham Amal. NeuroNOS is advancing BA-101 as a potential first-in-class therapy for glioblastoma, with the goal of translating these preclinical findings into future clinical development.
Key Questions Answered:
A: Glioblastoma is an incredibly smart, highly adaptable cancer. When you hit it with standard chemotherapy like temozolomide, the tumor cells don’t just sit there; they mutate and ramp up production of an enzyme called nNOS. This enzyme pumps out a massive flood of nitric oxide molecules, creating a state of “nitrosative stress.” This chemical shield essentially neutralizes the chemotherapy, allowing the cancer cells to safely repair their DNA, multiply, and spread throughout the brain completely unhindered.
A: BA-101 acts like a precision missile aimed directly at the tumor’s chemical shield. It functions as a highly selective neuronal nitric oxide synthase (nNOS) inhibitor. By locking onto this specific enzyme, BA-101 completely cuts off the tumor’s ability to manufacture excessive nitric oxide. Without that protective barrier, the glioblastoma cells lose their structural stability, their ability to migrate into healthy tissue is paralyzed, and their internal defense system drops, allowing standard temozolomide to break back inside and destroy the cancer’s DNA.
A: While these results are a massive win for translational medicine, it is important to remember that BA-101 is still in the preclinical testing phase. Professor Haitham Amal and his startup NeuroNOS have officially secured the licensing rights to transition this compound out of academic labs and into industrial manufacturing. The team must complete further safety testing and regulatory screenings before launching Phase I human clinical trials, a process that typically takes a few years but offers an incredibly hopeful roadmap for one of the world’s deadliest cancers.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this brain cancer research news
Author: Danae Marx
Source: Hebrew University of Jerusalem
Contact: Danae Marx – Hebrew University of Jerusalem
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor” by Mallikarjuna Nimgampalle, Shashank Kumar Ojha, Maryam Kartawy, Michelle Feivelson, Haitham Amal. Cancer Medicine
DOI:10.1002/cam4.72067
Abstract
Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
Background and Purpose
The treatment of glioblastoma remains a major clinical challenge, largely due to intrinsic and acquired resistance to Temozolomide (TMZ). We aim to advance a novel therapeutic approach to overcome TMZ resistance in human glioblastoma by using the neuronal nitric oxide synthase inhibitor BA-101 as both a monotherapy and an adjuvant therapy. This approach leverages the additive anti-cancer activity of BA-101 to enhance the efficacy of TMZ and thereby improve treatment outcomes for glioblastoma patients.
Experimental Approach
We used TMZ-resistant human glioblastoma LN-18 and LN-229 cells to study the therapeutic potential and additive anticancer activity of nNOS inhibitor BA-101 using in vitro cancer functional assays, including cell proliferation, cell invasion, and migration assays, and biochemical assessment of biomarkers for nitrosative stress, and apoptosis using western blot analysis, flow cytometry and AnnexinV/PI staining. We further performed an in vivo preclinical evaluation using an LN-229 xenograft tumor model in SCID mice.
Key Results
Our findings demonstrate that BA-101 displays significant anti-cancer activity and sensitizes resistant glioblastoma cells to TMZ, reducing nitrosative stress, inhibiting clonogenic growth, invasion and migration, and promoting apoptotic cell death. It also demonstrates a significant decrease in tumor volume, suggesting that BA-101 exerts additive anti-tumor activity when used as an adjuvant to TMZ in SCID mice bearing LN 229 xenografts.
Conclusions and Implications
Collectively, our findings strongly suggest that BA-101 has potential for further preclinical and translational development as an anticancer agent and a novel TMZ chemosensitizer for GBM therapy.
